Search Result
Results for "
HIV integrase
" in MedChemExpress (MCE) Product Catalog:
17
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-13238
-
Dolutegravir
Maximum Cited Publications
32 Publications Verification
S/GSK1349572
|
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-10353
-
-
-
- HY-14740
-
|
GS-9137; JTK-303; D06677
|
HIV Integrase
HIV
|
Infection
|
|
Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
|
-
-
- HY-17605
-
-
-
- HY-10353A
-
-
-
- HY-13238A
-
|
S/GSK1349572 sodium
|
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-N0457A
-
|
(-)-Chicoric acid; trans-Caffeoyltartaric acid
|
HIV Integrase
HIV
Endogenous Metabolite
|
Infection
Cancer
|
|
L-Chicoric Acid ((-)-Chicoric acid) is a dicaffeoyltartaric acid and a potent, selective and reversible HIV-1 integrase inhibitor with an IC50 of ~100 nM. L-Chicoric Acid inhibits HIV-1 replication in tissue culture .
|
-
-
- HY-I0096
-
|
|
iGluR
HIV
HIV Integrase
|
Neurological Disease
|
|
Indole-2-carboxylic acid (I2CA) is a competitive antagonist of the glycine site of the NMDA receptor (Ki=15 μM, 5-fluoro-I2CA) and an inhibitor of HIV-1 integrase. Indole-2-carboxylic acid is selective for the glycine site of the NMDA receptor and blocks the enhancement of NMDA receptor by competitively inhibiting the binding of glycine to the NMDA receptor. Indole-2-carboxylic acid can also inhibit the strand transfer activity of HIV-1 integrase by chelating Mg 2+ at the active site of integrase and interacting with the hydrophobic cavity. Indole-2-carboxylic acid can be used in the study of neurological diseases (such as stroke, epilepsy) and HIV-1 infection .
|
-
-
- HY-W010937
-
|
BMIM-TFSI; BMI-TFSI
|
HIV
HIV Integrase
|
Infection
|
|
1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide (BMIM-TFSI; BMI-TFSI) is an HIV-1 integrase inhibitor. 1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide weakly inhibits recombinant HIV-1 integrase 3'-processing or strand transfer activity. 1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide can be used for the research of HIV-1 .
|
-
-
- HY-B1408
-
|
2-Hydroxybenzanilide
|
Environmental Pollutants
HIV Integrase
HIV
|
Infection
|
|
Salicylanilide demonstrates a wide range of biological activities including antiviral potency which can inhibit HIV virus
by targeting HIV-1 integrase or reverse transcriptase.
|
-
-
- HY-100083
-
|
|
HIV
Drug Intermediate
|
Infection
|
|
Dolutegravir intermediate-1 (Compound 11) is a synthetic intermediate. Dolutegravir intermediate-1 can be used to synthesize Dolutegravir (HY-13238). Dolutegravir is an Integrase inhibitor with potential applications in HIV-1 infection research .
|
-
-
- HY-130000
-
|
STP0404
|
HIV Integrase
HIV
|
Infection
|
|
Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24,000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties .
|
-
-
- HY-108818
-
-
-
- HY-123572
-
-
-
- HY-18595
-
|
|
HIV
HIV Integrase
|
Infection
|
|
BI 224436 is a novel HIV-1 noncatalytic site integrase inhibitor with EC50 values of less than 15 nM against different HIV-1 laboratory strains.
|
-
-
- HY-17605A
-
|
GS-9883 sodium
|
HIV Integrase
HIV
|
Infection
|
|
Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity .
|
-
-
- HY-13269
-
|
|
HIV
HIV Integrase
|
Infection
Inflammation/Immunology
|
|
BMS-707035 is a potent orally active HIV-1 integrase strand transfer inhibitor (INSTI). BMS-707035 has enzyme inhibitory with an IC50 value of 3 nM. BMS-707035 also has weak CYP inhibiton and antiviral activity. BMS-707035 can be used for the research of human immunodeficiency virus-1 (HIV-1) .
|
-
-
- HY-18601
-
|
|
HIV
HIV Integrase
|
Infection
|
|
(±)-BI-D is a potent ALLINI (allosteric integrase inhibitor). (±)-BI-D binds integrase at the LEDGF/p75 binding site. (±)-BI-D inhibits HIV-Luc infection in cells (IC50: 0.16 μM in Psip1 knockout E9 mouse embryonic fibroblasts, 2.9 μM in wild-type E9 mouse embryonic fibroblasts) .
|
-
-
- HY-108935
-
|
|
HIV Integrase
GLUT
Tyrosinase
|
Cancer
|
|
Lavendustin B is an inhibitor of HIV-1 integrase interaction with LEDGF/p75 with an IC50 of 94.07 μM. Lavendustin B is an ATP-competitive GLUT1 inhibitor with a Ki of 15 μM. Lavendustin B is also a weak inhibitor of tyrosine kinases .
|
-
-
- HY-107485
-
-
-
- HY-10522
-
LEDGIN6
4 Publications Verification
CX05168; CX04328
|
HIV
HIV Integrase
|
Infection
|
|
LEDGIN6 (CX05168) is a quinoline-based protein-protein interaction inhibitor of LEDGF/p75 and HIV integrase .
|
-
-
- HY-13025
-
|
|
HIV
HIV Integrase
|
Infection
|
|
HIV-1 integrase inhibitor is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
-
- HY-N16050
-
|
Ethyl salvionolate A
|
HIV
Reverse Transcriptase
HIV Integrase
HIV Protease
|
Infection
|
|
Ethyl salvianolate A (Ethyl salvionolate A) is an anti-HIV-1 compound that can be extracted from the roots of Salvia yunnanensis. Ethyl salvianolate A inhibits P24 antigen in HIV-1 infected MT-4 cell cultures (EC50: 1.44 μg/mL). Ethyl salvianolate A inhibits HIV-1 replicative enzymes, with IC50s of 56.38 μM (Reverse transcriptase), 12.03 μM (Protease), 14.54 μM (Integrase), respectively .
|
-
-
- HY-134851
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC50s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC50s ranging from 0.9 to 1.5 μM .
|
-
-
- HY-17605S
-
|
|
Isotope-Labeled Compounds
|
Infection
|
|
Bictegravir- 15N,d2 (GS-9883- 15N,d2) is the 15N and deuterium labeled Bictegravir (HY-17605) . Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM .
|
-
-
- HY-17605AR
-
|
GS-9883 sodium (Standard)
|
Reference Standards
HIV Integrase
HIV
|
Infection
|
|
Bictegravir (sodium) (Standard) is the analytical standard of Bictegravir (sodium). This product is intended for research and analytical applications. Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity .
|
-
-
- HY-153094
-
|
|
HIV
HIV Integrase
|
Infection
|
|
BDM-2 is an IN-LEDGF allosteric inhibitor (INLAI) of HIV-1 integrase (IN refers to integrase) (IC50=47 nM) with potent anti-Retroviral (ARV) activity. BDM-2 shows IN multimerization activation effect with an AC50 value of 20 nM. BDM-2 blocks the interaction between the catalytic core domain of IN (IN-CCD) and the Integrase binding domain of LEDGF/p75 (IBD), with an IC50 value of 0.15 μM. BDM-2 exhibits highly selective and favorable cytotoxicity .
|
-
-
- HY-177098
-
|
|
HIV
HIV Integrase
|
Infection
|
|
Lepetegravir (Example 24) is a HIV integrase inhibitor. Lepetegravir has antiviral effects (EC50: 0.98 nM in MT-4 cells) .
|
-
-
- HY-117879
-
|
|
HIV
HIV Integrase
|
Infection
|
|
PF-4776548 is a highly potent HIV integrase inhibitor. PF-477654 blocks the process of integrating HIV viral DNA into the host cell genome. PF-4776548 is promising for research of AIDS .
|
-
-
- HY-159092
-
|
|
HIV Integrase
|
Infection
|
|
HIV-1 integrase inhibitor 13 (Compound 15) is an inhibitor for HIV-1 integrase with an IC50 of 1.8 nM. HIV-1 integrase inhibitor 13 inhibits the HIV-1 WT and HIV-1 T125A, with IC50 of 21 and 580 nM, respectively .
|
-
-
- HY-130760
-
|
|
HIV Integrase
|
Infection
|
|
HIV-1 integrase inhibitor 7 is a potent HIV-1 integrase inhibitor, with an IC50 of 33.3 nM .
|
-
-
- HY-150079
-
|
|
HIV Integrase
|
Infection
|
|
HIV-1 integrase inhibitor 10 is an orally active HIV-1 allosteric integrase inhibitor (ALLINI). HIV-1 integrase inhibitor 10 can inhibit viral outgrowth of the NLRepRluc virus in MT-2 cells with EC50 values of 3-5 nM. HIV-1 integrase inhibitor 10 can be used for the research of Human immunodeficiency virus-1 (HIV-1) .
|
-
-
- HY-108820
-
|
|
HIV Integrase
HIV
|
Infection
|
|
HIV-1 integrase inhibitor 4 is a HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 3.7 nM.
|
-
-
- HY-108817
-
|
|
HIV Integrase
HIV
|
Infection
|
|
HIV-1 integrase inhibitor 3 is a HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 2.7 nM.
|
-
-
- HY-177670A
-
|
AR177 sodium; T30177 sodium
|
HIV
|
Infection
|
|
Zintevir sodium is an antisense oligonucleotide that targets HIV-1 integrase.
|
-
-
- HY-177670
-
|
AR177; T30177
|
HIV
|
Infection
|
|
Zintevir is an antisense oligonucleotide that targets HIV-1 integrase.
|
-
-
- HY-W507252
-
|
|
HIV Integrase
|
Infection
|
|
HIV-1 integrase inhibitor 11 (compound 5) is a potent inhibitor of HIV-1 integrase, with the IC50 of 125 μM .
|
-
-
- HY-N7330
-
|
|
HIV Integrase
HIV
|
Infection
|
|
Integracin B is a potent dimeric alkyl aromatic inhibitor of HIV-1 integrase discovered from the screening of fungal extracts using an in vitro assay. Integracin B inhibits both coupled and strand transfer activity of HIV-1 integrase .
|
-
-
- HY-159091
-
|
|
HIV Integrase
|
Infection
|
|
HIV-1 integrase inhibitor 12 (Compound 17) is an inhibitor for HIV-1 integrase with an IC50 of 1.4 nM. HIV-1 integrase inhibitor 12 inhibits the HIV-1 WT and HIV-1 T125A, with IC50 of 7.4 and 120 nM, respectively. HIV-1 integrase inhibitor 12 exhibits metabolic stability and Caco-2 permeability, and good pharmacokinetic characteristics with good bioavailability (64%) and low clearance (0.16 L/hr/kg) in rats .
|
-
-
- HY-147653
-
|
|
HIV Integrase
|
Infection
|
|
Integrase-LEDGF/p75 allosteric inhibitor 1 (Compound 31h) is an orally active integrase-LEDGF/p75 (IN-LEDGF/p75) allosteric inhibitor. Integrase-LEDGF/p75 allosteric inhibitor 1 inhibits HIV-1 DNA integration and shows antiviral activity with an EC50 of 3.9 nM against HIV-1 recombinant molecular clone NL432 .
|
-
-
- HY-132572
-
|
|
HIV
|
Infection
|
|
HIV-1 integrase inhibitor 9 (compound 8a) is a potent HIV-1 RNase H inhibitor with an IC50 of 12.3 μM. HIV-1 integrase inhibitor 9 shows an antiviral activity .
|
-
-
- HY-10353B
-
|
MK 0518 sodium
|
HIV Integrase
HIV
|
Infection
Cancer
|
|
Raltegravir (MK 0518) sodium is a potent and orally active integrase (IN) inhibitor, used to treat HIV infection.
|
-
-
- HY-177071
-
|
|
HIV
|
Infection
|
|
Asuptegravir (Compound 1) is an inhibitor of HIV integrase activity. Asuptegravir inhibits HIV in HEK293T cells (EC50 = 1.08 nM). Asuptegravir can be studied in anti-AIDs/HIV research .
|
-
-
- HY-12108
-
|
|
HIV Integrase
HIV
|
Infection
|
|
S 1360 is a potent and selective inhibitor of HIV-1 integrase. S 1360 inhibits the catalytic activity of purified integrase (
IC50: 20 nM). The EC50, and CC50 of S 1360
in MTT assay (MT-4 cells infected with HIV-1 IIIB) are 200 nM and 12 μM, respectively. S 1360 has antiviral activity against both X4 tropic and R5 tropic strains, as well as NRTI, NNRTI and PI drug-resistant variants .
|
-
-
- HY-17605S1
-
-
-
- HY-17605R
-
|
GS-9883 (Standard)
|
Reference Standards
HIV
HIV Integrase
|
Infection
|
|
Bictegravir (Standard) is the analytical standard of Bictegravir. This product is intended for research and analytical applications. Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
|
-
-
- HY-13238S1
-
|
S/GSK1349572-d3
|
Isotope-Labeled Compounds
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir-d3 is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-13238S2
-
|
S/GSK1349572-d5
|
Isotope-Labeled Compounds
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir-d5 is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-B1408R
-
|
2-Hydroxybenzanilide (Standard)
|
HIV Integrase
HIV
Reference Standards
|
Infection
|
|
Salicylanilide (Standard) is the analytical standard of Salicylanilide. This product is intended for research and analytical applications. Salicylanilide demonstrates a wide range of biological activities including antiviral potency which can inhibit HIV virus
by targeting HIV-1 integrase or reverse transcriptase.
|
-
-
- HY-14740R
-
|
GS-9137 (Standard); JTK-303 (Standard); D06677 (Standard)
|
Reference Standards
HIV Integrase
HIV
|
Infection
|
|
Elvitegravir (Standard) is the analytical standard of Elvitegravir. This product is intended for research and analytical applications. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
|
-
- HY-13238R
-
|
S/GSK1349572 (Standard)
|
Reference Standards
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir (Standard) is the analytical standard of Dolutegravir. This product is intended for research and analytical applications. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
- HY-16907
-
|
S/GSK-364735
|
HIV
HIV Integrase
|
Infection
|
|
GSK-364735 is a potent antiretroviral agent against human immunodeficiency virus type 1 (HIV-1) and serves as an integrase inhibitor with an IC50 of 8 ± 2 nM. GSK-364735 can be utilized in antiviral research .
|
-
- HY-18666
-
|
|
HIV
|
Infection
|
|
D77 is anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. D77 inhibits HIV-1(IIIB) replication by EC50 value of 23.8 μg/ml in MT-4 cell (5.03 μg/ml for C8166 cells).
|
-
- HY-176960
-
|
|
Biochemical Assay Reagents
|
Others
|
|
3-Amino-2-hydroxypropyl dihydrogen phosphate is a chemical modification complex of the DNA phosphate backbone, which can be used to study the interaction between HIV integrase (IN) and DNA .
|
-
- HY-15592AS
-
|
GSK-1265744-d3 sodium; S/GSK1265744-d3 sodium
|
Isotope-Labeled Compounds
HIV Integrase
|
Infection
|
|
Cabotegravir-d3 (sodium) is the deuterium labeled Cabotegravir sodium. Cabotegravir sodium is a highly potent HIV integrase inhibitor with an IC50 value of 2.5 nM for HIVADA. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltr
|
-
- HY-161945
-
|
|
HIV
HIV Integrase
|
Infection
|
|
IN-RNA-IN-2 (compound 1a) is an inhibitor (IC50=70 nM) of the interaction between HIV-1 integrase and the viral RNA genome. IN-RNA-IN-2 exerts its anti-HIV activity by inhibiting the viral replication process .
|
-
- HY-W749636
-
-
- HY-122256
-
|
|
HIV Integrase
|
Infection
|
|
L-870812 is a HIV-1 integration with integrase strand transfer inhibitor. L-870812 consistently blocks cell-free and cell-associated HIV-1 infection. L-870812 blocks subtype C and CRFO2_AG primary isolates. L-870812 can be used for the study of replication-deficient HIV-1 Ba-L (env) pseudovirus .
|
-
- HY-153247
-
-
- HY-107485R
-
|
|
Reference Standards
HIV Integrase
|
Infection
|
|
HIV-1 integrase inhibitor 8 (Standard) is the analytical standard of HIV-1 integrase inhibitor 8 (HY-107485). This product is intended for research and analytical applications. HIV-1 integrase inhibitor 8 is a HIV-1 integrase inhibitor, compound 8 .
|
-
- HY-N15327
-
|
|
HIV
HIV Integrase
|
Infection
|
|
Hyrtiosal, found in the marine sponge Hyrtios erectus, is an inhibitor of the N-terminal domain (NTD) of HIV-1 integrase (HIV-1 IN) with an IC50 value of 9.60-0.86 μM. Hyrtiosal binds to the Ser17, Trp19, and Lys34 sites on the NTD of HIV-1 IN, inhibiting the binding of HIV-1 viral DNA to integrase and interfering with the formation of the pre-integrated complex of HIV-1. Hyrtiosal is promising for research of anti-HIV agents .
|
-
- HY-17605S2
-
|
GS-9883-d4
|
HIV
HIV Integrase
|
Infection
|
|
Bictegravir-d4 is a deuterium of Bictegravir (HY-17605). Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM .
|
-
- HY-10353S
-
-
- HY-163177
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-63 (compound S17) is a potent HIV-1 inhibitor. HIV-1 inhibitor-63 inhibits integrase-Ku70 complex formation with an IC50 value of 12 µM. HIV-1 inhibitor-63 inhibits HIV-1 post-integration DNA repair .
|
-
- HY-14740S
-
|
GS-9137-d8; JTK-303-d8; D06677-d8
|
Isotope-Labeled Compounds
HIV Integrase
HIV
|
Infection
|
|
Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
|
-
- HY-A0162R
-
|
|
Antibiotic
Reference Standards
Bacterial
|
Infection
|
|
Bictegravir (sodium) (Standard) is the analytical standard of Bictegravir (sodium). This product is intended for research and analytical applications. Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity .
|
-
- HY-10353S1
-
-
- HY-P2379
-
|
|
HIV Integrase
|
Infection
|
|
His-Cys-Lys-Phe-Trp-Trp is an inhibitor for the human immunodeficiency virus (HIV) integrase with an IC50 of 2 μM .
|
-
- HY-17605S4
-
-
- HY-W103287
-
|
|
HIV Integrase
|
Infection
|
|
Hydroxyisoquinoline-1,3(2H,4H)-dione (compound 6a) is a HIV-1 integrase (IN) and HIV-1 reverse transcriptase (RT) ribonuclease H (RNase H) inhibitor with an IC50 value of 6.32, 5.9 µM, respectively .
|
-
- HY-N0457AR
-
|
(-)-Chicoric acid (Standard); trans-Caffeoyltartaric acid (Standard)
|
Reference Standards
HIV Integrase
HIV
Endogenous Metabolite
|
Infection
Cancer
|
|
L-Chicoric Acid (Standard) is the analytical standard of L-Chicoric Acid. This product is intended for research and analytical applications. L-Chicoric Acid ((-)-Chicoric acid) is a dicaffeoyltartaric acid and a potent, selective and reversible HIV-1 integrase inhibitor with an IC50 of ~100 nM. L-Chicoric Acid inhibits HIV-1 replication in tissue culture .
|
-
- HY-122229
-
|
|
HIV
|
Infection
|
|
GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC50 of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys .
|
-
- HY-14740S2
-
|
GS-9137-13C6 ; JTK-303-13C6 ; D06677-13C6
|
Isotope-Labeled Compounds
HIV Integrase
HIV
|
Infection
|
|
Elvitegravir- 13C6 (GS-9137- 13C6) is 13C labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
|
-
- HY-14740S1
-
|
GS-9137-d6; JTK-303-d6; D06677-d6
|
Isotope-Labeled Compounds
HIV Integrase
HIV
|
Infection
|
|
Elvitegravir-d6 (GS-9137-d6) is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively .
|
-
- HY-10353AS
-
-
- HY-N11288
-
|
|
HIV
|
Infection
|
|
Methyl salvionolate A is a potent inhibitor of HIV-1. Methyl salvionolate A inhibits P24 antigen in HIV-1 infected MT-4 cell with an EC50 of 1.62 μg/ml. Methyl salvionolate A also inhibits HIV-1 reverse transcriptase, protease and integrase with
IC50s of 50.58, 10.73 and 7.58 μg/ml, respectively .
|
-
- HY-10353AR
-
|
MK 0518 potassium (Standard)
|
Reference Standards
HIV Integrase
HIV
|
Infection
Cancer
|
|
Raltegravir (potassium) (Standard) is the analytical standard of Raltegravir (potassium). This product is intended for research and analytical applications. Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
|
-
- HY-12210
-
|
|
HIV Integrase
|
Infection
|
|
(S)-BI-1001 (Compound 11) is an active S-enantiomer of BI-1001. (S)-BI-1001 exhibits antiviral potency against HIV-1 integrase with an IC50 of 28 nM, an EC50 of 450 nM and a Kd of 4.7 μM .
|
-
- HY-16907A
-
|
S/GSK-364735 potassium
|
HIV
HIV Integrase
|
Infection
|
|
GSK-364735 potassium (S/GSK-364735 potassium) is the potassium salt form of GSK-364735 (HY-16907). GSK-364735 potassium is an antiretroviral, that inhibits the integrase of human immunodeficiency virus type 1 (HIV-1) with an IC50 of 7.8 nM .
|
-
- HY-16907B
-
|
S/GSK-364735 sodium
|
HIV
HIV Integrase
|
Infection
|
|
GSK-364735 sodium (S/GSK-364735 sodium) is the sodium salt form of GSK-364735 (HY-16907). GSK-364735 sodium is an antiretroviral, that inhibits the integrase of human immunodeficiency virus type 1 (HIV-1) with an IC50 of 7.8 nM .
|
-
- HY-10353AS2
-
-
- HY-10353AS1
-
-
- HY-15592S2
-
|
GSK-1265744-d3-1; S/GSK1265744-d3-1
|
Isotope-Labeled Compounds
HIV Integrase
|
Infection
|
|
Cabotegravir d3-1 (GSK-1265744-d3-1) is a deuterium substitute of Cabotegravir. Cabotegravir is a potent HIV integrase inhibitor used in AIDS research
|
-
- HY-13269R
-
|
|
HIV
HIV Integrase
|
Infection
Inflammation/Immunology
|
|
BMS-707035 (Standard) is the analytical standard of BMS-707035. This product is intended for research and analytical applications. BMS-707035 is a potent orally active HIV-1 integrase strand transfer inhibitor (INSTI). BMS-707035 has enzyme inhibitory with an IC50 value of 3 nM. BMS-707035 also has weak CYP inhibiton and antiviral activity. BMS-707035 can be used for the research of human immunodeficiency virus-1 (HIV-1) .
|
-
- HY-185448
-
|
|
HIV
HIV Integrase
|
Infection
|
|
HIV RT-IN-1 is an inhibitor of HIV integrase and HIV reverse transcriptase-associated ribonuclease H. HIV RT-IN-1 is applicable to research related to HIV-1 infection .
|
-
- HY-182277
-
|
|
HIV Integrase
HIV
|
Infection
|
|
GSK-1264 is an HIV-1 integrase inhibitor. GSK-1264 binds to a site spanning the HIV-1 integrase catalytic core domain and C-terminal domain, mediates formation of an open polymer of HIV-1 integrase dimers via inhibitor-bridged contacts between adjacent dimers. GSK-1264 disrupts late-stage HIV replication by interfering with viral particle assembly. GSK-1264 stimulates inappropriate polymerization of HIV-1 integrase. GSK-1264 can be used for the research of HIV infection .
|
-
- HY-108818R
-
|
|
Reference Standards
HIV Integrase
|
Infection
|
|
XZ426 (Standard) is the analytical standard of XZ426 (HY-108818). This product is intended for research and analytical applications. XZ426 is a potent integrase strand transfer inhibitor with anti- HIV activity .
|
-
- HY-182678
-
|
|
HIV Integrase
|
Infection
|
|
L-731988 is an inhibitor targeting HIV-1 integrase. L-731988 inhibits HIV-1 replication by blocking integrase function. L-731988 exhibits ED50 values ranging from 0.5 μM to 3.14 μM against various HIV-1 isolates. L-731988 can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .
|
-
- HY-N18192
-
|
|
HIV
HIV Integrase
|
Infection
|
|
Kuwanon L is an HIV-1 integrase (HIV-1 integrase) inhibitor, with IC50 values of 42 μM and 34 μM for LEDGF-dependent and LEDGF-independent integrase, respectively. Kuwanon L blocks the interaction between HIV-1 integrase and LEDGF/p75, with an IC50 of 22 μM. Kuwanon L inhibits HIV-1 replication in immune cells. Kuwanon L is applicable to research related to HIV-1 infection .
|
-
- HY-183926
-
|
|
HIV Integrase
|
Infection
|
|
D719 is an HIV-1 integrase inhibitor. D719 binds to the hydrophobic pocket of HIV-1 integrase CCD dimer, disrupts interaction with LEDGF/P75, and prevents integrase nuclear translocation. D719 reduces HIV-1 p24 antigen production in acute infection of human T cells. D719 can be used for the research of HIV infection .
|
-
- HY-178833
-
-
- HY-W876243
-
|
|
Drug Derivative
HIV Integrase
|
Infection
|
|
Averionol (Compound 26) is a flavonoid compound. Averionol has no significant inhibitory activity against HIV integrase. Averionol can be used in the development of anti-HIV agents .
|
-
- HY-N16888
-
|
|
HIV Integrase
Reverse Transcriptase
|
Infection
|
|
Peruvianoside II is a flavanone glucoside compound. Peruvianoside II shows no inhibitory activity against both HIV-1 reverse transcriptase and HIV-1 integrase at concentrations below 100 μM. Peruvianoside II can be extracted from the leaves of Thevetia peruviana .
|
-
- HY-N17982
-
|
|
HIV Integrase
|
Infection
|
|
Vanillic acid 4-O-β-D-glucopyranoside is a vanillic acid glycoside with moderate antioxidant activity. Vanillic acid 4-O-β-D-glucopyranoside scavenges DPPH free radicals and superoxide anion radicals, and inhibits AAPH-induced lipid peroxidation in the linoleic acid system. The IC50 value of Vanillic acid 4-O-β-D-glucopyranoside against HIV-1 integrase is >100 μg/mL, indicating that it is not an effective HIV-1 integrase inhibitor. Vanillic acid 4-O-β-D-glucopyranoside is isolable from the ethyl acetate extract of Gardeniae Fructus.
|
-
- HY-123883
-
|
|
HIV
HIV Integrase
|
Infection
|
|
MK-0536 is a highly potent HIV-1 integrase inhibitor that effectively suppresses the replication of wild-type viruses. MK-0536 retains significant antiviral activity against multiple key drug-resistant mutants such as Y143R and N155H, and shows no toxicity to uninfected cells. MK-0536 selectively blocks the strand transfer reaction of integrase by chelating magnesium ions at the active site and interacting with viral DNA and enzyme residues. MK-0536 is applicable to the study of HIV infection mechanisms .
|
-
- HY-123066A
-
|
|
Drug Isomer
|
Others
|
|
(E)-DIDS monohydrate sodium is the E-isomer of DIDS monohydrate sodium (HY-123066). DIDS is a hRAD51 inhibitor with an IC50 value of 90 μM. DIDS exhibits significant inhibitory activity against HIV-1 integrase with an IC50 value of 5 μM .
|
-
- HY-10353R
-
|
MK-0518 (Standard)
|
Reference Standards
HIV Integrase
HIV
|
Infection
Cancer
|
|
Raltegravir (Standard) is the analytical standard of Raltegravir (HY-10353). This product is intended for research and analytical applications. Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.
|
-
- HY-14740S3
-
|
GS-9137-d5; JTK-303-d5; D06677-d5
|
Isotope-Labeled Compounds
HIV
HIV Integrase
|
Infection
|
|
Elvitegravir-d5 (GS-9137-d5; JTK-303-d5; D06677-d5) is the deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
|
-
- HY-N15438
-
|
|
HIV
HIV Integrase
|
Infection
|
|
Herbacitrin is a HIV-1 reverse transcriptase and integrase inhibitor with IC50 values of 21.5 μM and 2.15 μM, respectively. Herbacitrin inhibits the growth of normal mouse embryonic cells, hybridoma HF cells, and ras/myc-transformed SFME cells, regulates the growth of ras-transformed SFME cells, and exhibits cytotoxic activity against hybridoma HF cells. Herbacitrin can be used in studies related to HIV-1 infection .
|
-
- HY-100083R
-
|
|
Reference Standards
HIV
|
Others
|
|
Dolutegravir intermediate-1 (Standard) is the analytical standard of Dolutegravir intermediate-1 (HY-100083). This product is intended for research and analytical applications. Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection.
|
-
- HY-10522R
-
|
CX05168 (Standard); CX04328 (Standard)
|
Reference Standards
HIV
HIV Integrase
|
Infection
|
|
LEDGIN6 (Standard) is the analytical standard of LEDGIN6 (HY-10522). This product is intended for research and analytical applications. LEDGIN6 (CX05168) is a quinoline-based protein-protein interaction inhibitor of LEDGF/p75 and HIV integrase .
|
-
- HY-150080
-
|
BMS-986180
|
HIV
HIV Integrase
|
Infection
|
|
GSK3739936 (BMS-986180) is a potent HIV-1 allosteric integrase inhibitor with an IC50 value of 11.1 nM and an EC50 value of 1.7 nM. GSK3739936 is also a weak CYP inhibitor (IC50>24.3 μM). GSK3739936 shows favorable pharmacokinetic property in preclinical species with rapid absorption, low to moderate clearance and excellent oral bioavailability .
|
-
- HY-18257
-
|
|
Antibiotic
Bacterial
Dengue Virus
Amyloid-β
HIV Integrase
|
Infection
Neurological Disease
Inflammation/Immunology
|
Rolitetracycline is a highly soluble, broad-spectrum antibiotic derived from tetracycline. Rolitetracycline binds to and stabilizes bovine serum albumin, and also inhibits HIV-1 integrase, blocks Aβ fibril formation and suppresses dengue virus proliferation. Rolitetracycline mediates the inhibition of Aβ fibrils via a specific three-dimensional pharmacophore conformation, and exerts bacteriostatic and bactericidal activities. Rolitetracycline acts synergistically with Penicillin G (HY-N7139) or Cephalothin (HY-B1275A) to alter the effects on microbial growth. Rolitetracycline serves as an important tool compound for the study of bacterial infections (urinary tract infections, sepsis), HIV-1 and dengue virus infections, as well as Alzheimer's disease .
|
-
- HY-N6711
-
|
|
HIV Integrase
Bacterial
Antibiotic
Reactive Oxygen Species (ROS)
STAT
AMPK
11β-HSD
|
Infection
Metabolic Disease
|
|
Equisetin is an N-methylserine-derived acyl tetramic acid, quorum sensing inhibitor (QSI), herbicides and antibiotics. Equisetin specifically inhibits the anionic carriers of substrates in the inner mitochondrial membrane. Equisetin inhibits the activity of HIV-1 integrase, 11β-HSD1, and 2,4-dinitrophenol (Dnp)-stimulated ATPase (IC50 = ~8 nmol per mg of protein). Equisetin exhibits growth inhibition of bacteria, anti-inflammatory, amelioration of lipid-associated disorders, and cytotoxic effects .
|
-
- HY-15592A
-
|
GSK-1265744 sodium; S/GSK1265744 sodium
|
OAT
HIV
HIV Integrase
|
Infection
|
|
Cabotegravir (GSK-1265744) sodium is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir sodium can be used to research AIDS .
|
-
- HY-15592
-
|
GSK-1265744; S/GSK1265744
|
OAT
HIV
HIV Integrase
|
Infection
|
|
Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .
|
-
- HY-15592R
-
|
GSK-1265744 (Standard); S/GSK1265744 (Standard)
|
OAT
Reference Standards
HIV
HIV Integrase
|
Infection
|
|
Cabotegravir (Standard) is the analytical standard of Cabotegravir. This product is intended for research and analytical applications. Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .
|
-
- HY-185449
-
|
|
HIV
Reverse Transcriptase
DNA/RNA Synthesis
|
Infection
|
|
HIV RT-IN-2 is a HIV reverse transcriptase inhibitor with an IC50 value of 1.2 μM for HIV-1 RT RNA-dependent DNA polymerase. HIV RT-IN-2 potently inhibits all three modes of HIV-1 RT-associated RNase H activity (internal, 3'-DNA directed, 5'-RNA directed cleavage) and inhibits HIV-1 replication. HIV RT-IN-2 can be used for the research of HIV-1 infection .
|
-
- HY-111832
-
|
TeGG
|
UGT
|
Infection
Metabolic Disease
|
|
1,2,3,6-Tetragalloylglucose (TEgG) is a competitive inhibitor of UDP-glucuronyltransferase UGT1A1, targeting the competitive substrate binding site of UGT1A1. 1,2,3,6-Tetragalloylglucose inhibits UGT1A1-mediated β-estradiol 3-glucuronidation and SN-38 glucuronidation with IC50 of 6.01 μM and 4.31 μM, respectively, and binds to UGT1A1 with Ki of 3.55 μM. 1,2,3,6-Tetragalloylglucose also induces tumor cell apoptosis, inhibit cell proliferation, activates caspase-3 and induces DNA fragmentation in HL-60 cells. 1,2,3,6-Tetragalloylglucose also inhibits HIV integrase and reverse transcriptase, and inhibits HCV protease .
|
-
- HY-N16872
-
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-A0162R
-
|
|
Antibiotic
Reference Standards
Bacterial
|
Infection
|
|
Bictegravir (sodium) (Standard) is the analytical standard of Bictegravir (sodium). This product is intended for research and analytical applications. Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity .
|
-
- HY-P2379
-
|
|
HIV Integrase
|
Infection
|
|
His-Cys-Lys-Phe-Trp-Trp is an inhibitor for the human immunodeficiency virus (HIV) integrase with an IC50 of 2 μM .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-111832
-
|
TeGG
|
other families
Classification of Application Fields
Phenols
Polyphenols
Metabolic Disease
Plants
Disease Research Fields
Source Classification
|
UGT
|
|
1,2,3,6-Tetragalloylglucose (TEgG) is a competitive inhibitor of UDP-glucuronyltransferase UGT1A1, targeting the competitive substrate binding site of UGT1A1. 1,2,3,6-Tetragalloylglucose inhibits UGT1A1-mediated β-estradiol 3-glucuronidation and SN-38 glucuronidation with IC50 of 6.01 μM and 4.31 μM, respectively, and binds to UGT1A1 with Ki of 3.55 μM. 1,2,3,6-Tetragalloylglucose also induces tumor cell apoptosis, inhibit cell proliferation, activates caspase-3 and induces DNA fragmentation in HL-60 cells. 1,2,3,6-Tetragalloylglucose also inhibits HIV integrase and reverse transcriptase, and inhibits HCV protease .
|
-
-
- HY-N0457A
-
-
-
- HY-I0096
-
|
|
Ketones, Aldehydes, Acids
Endogenous metabolite
Source Classification
|
iGluR
HIV
HIV Integrase
|
|
Indole-2-carboxylic acid (I2CA) is a competitive antagonist of the glycine site of the NMDA receptor (Ki=15 μM, 5-fluoro-I2CA) and an inhibitor of HIV-1 integrase. Indole-2-carboxylic acid is selective for the glycine site of the NMDA receptor and blocks the enhancement of NMDA receptor by competitively inhibiting the binding of glycine to the NMDA receptor. Indole-2-carboxylic acid can also inhibit the strand transfer activity of HIV-1 integrase by chelating Mg 2+ at the active site of integrase and interacting with the hydrophobic cavity. Indole-2-carboxylic acid can be used in the study of neurological diseases (such as stroke, epilepsy) and HIV-1 infection .
|
-
-
- HY-N6711
-
-
-
- HY-N16050
-
-
-
- HY-N7330
-
-
-
- HY-N15327
-
|
|
Other Terpenoids
Animals
Terpenoids
Source Classification
|
HIV
HIV Integrase
|
|
Hyrtiosal, found in the marine sponge Hyrtios erectus, is an inhibitor of the N-terminal domain (NTD) of HIV-1 integrase (HIV-1 IN) with an IC50 value of 9.60-0.86 μM. Hyrtiosal binds to the Ser17, Trp19, and Lys34 sites on the NTD of HIV-1 IN, inhibiting the binding of HIV-1 viral DNA to integrase and interfering with the formation of the pre-integrated complex of HIV-1. Hyrtiosal is promising for research of anti-HIV agents .
|
-
-
- HY-N0457AR
-
-
-
- HY-N11288
-
-
-
- HY-N18192
-
-
-
- HY-N16888
-
-
-
- HY-N17982
-
-
-
- HY-N15438
-
-
-
- HY-N16872
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-17605S
-
|
|
|
Bictegravir- 15N,d2 (GS-9883- 15N,d2) is the 15N and deuterium labeled Bictegravir (HY-17605) . Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM .
|
-
-
- HY-17605S1
-
|
|
|
Bictegravir-d5 is deuterated labeled Bictegravir (HY-17605). Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
|
-
-
- HY-13238S1
-
|
|
|
Dolutegravir-d3 is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-13238S2
-
|
|
|
Dolutegravir-d5 is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-15592AS
-
|
|
|
Cabotegravir-d3 (sodium) is the deuterium labeled Cabotegravir sodium. Cabotegravir sodium is a highly potent HIV integrase inhibitor with an IC50 value of 2.5 nM for HIVADA. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltr
|
-
-
- HY-17605S2
-
|
|
|
Bictegravir-d4 is a deuterium of Bictegravir (HY-17605). Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM .
|
-
-
- HY-10353S
-
|
|
|
Raltegravir-d4 is deuterium labeled Raltegravir. Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.
|
-
-
- HY-14740S
-
|
|
|
Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
|
-
-
- HY-10353S1
-
|
|
|
Raltegravir-d6 is a deuterated labeled Raltegravir . Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.
|
-
-
- HY-17605S4
-
|
|
|
Bictegravir-d7 (GS-9883-d7) is deuterium labeled Bictegravir. Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
|
-
-
- HY-14740S2
-
|
|
|
Elvitegravir- 13C6 (GS-9137- 13C6) is 13C labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
|
-
-
- HY-14740S1
-
|
|
|
Elvitegravir-d6 (GS-9137-d6) is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively .
|
-
-
- HY-10353AS
-
|
|
|
Raltegravir-d3 (potassium) is the deuterium labeled Raltegravir potassium. Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection .
|
-
-
- HY-10353AS2
-
|
|
|
Raltegravir-d4 (potassium) (MK 0518-d4 (potassium)) is deuterium labeled Raltegravir (potassium). Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
|
-
-
- HY-10353AS1
-
|
|
|
Raltegravir- 13C,d3 potassium is 13C labeled Raltegravir potassium (HY-10353A). Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
|
-
-
- HY-15592S2
-
|
|
|
Cabotegravir d3-1 (GSK-1265744-d3-1) is a deuterium substitute of Cabotegravir. Cabotegravir is a potent HIV integrase inhibitor used in AIDS research
|
-
-
- HY-14740S3
-
|
|
|
Elvitegravir-d5 (GS-9137-d5; JTK-303-d5; D06677-d5) is the deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-13025
-
|
|
|
Azide
|
|
HIV-1 integrase inhibitor is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
| Cat. No. |
Product Name |
|
Classification |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: